Pfizer repels Covid-19 sales tumble to raise 2026 guidance

Pfizer has upgraded the bottom-end of its full-year (FY) gross outlook by $500m arsenic show from the drugmaker's pb products much than compensated for weaker Covid-19-related sales.

Pfizer present expects 2026 gross to onshore betwixt $60.5bn and $62.5bn, up from the $59.5bn to $62.5bn scope it antecedently forecast.

According to the large pharma company, the revised outlook reflects a $1.5bn better-than-expected show from its non-Covid products. Sales for Covid-19 products, which see antiviral Paxlovid and mRNA vaccine Comirnaty, are conversely expected to bring successful $1bn less. The former's income were down 95% successful Q2, portion the second dropped 34%.

Pfizer emerged arsenic a pharmaceutical powerhouse during the pandemic, but little corruption rates and narrower usage cases mean its Covid-19 brands are impacting the company's bottommost line.

Pfizer inactive recorded revenues of $15bn successful Q2, up 3% from the aforesaid 4th successful 2025, meaning its non-Covid products much than offset headwinds. This fig bushed statement estimates, arsenic per Citi analysts.

Blood thinner Eliquis (apixaban), contempt suffering marketplace erosion owed to generic entry, grew 19% to scope $2.4bn successful income globally for the quarter. Antibody cause conjugate (ADC) Padcev (enfortumab vedotin) grew 23%, portion uncommon illness medicine household Vyndaqel (tafamidis) accrued 8%.

However, Pfizer revealed that it is present targeting an further $2.5bn successful outgo savings betwixt 2027 and 2029. This means that its outgo savings programme, archetypal unveiled successful precocious 2023, present sits astatine much than $10bn aft undergoing aggregate expansions.

Pfizer's CEO Albert Bourla said: "Pfizer had different beardown quarter, delivering connected our fiscal commitments and advancing our strategy. Our launched and acquired products performed well, our obesity programme is advancing with meaningful momentum, and our oncology portfolio remains a root of strength."

Bourla oversaw a fig of high-profile deals successful 2025 arsenic the institution looked to cement its post-Covid future. In November 2025, Pfizer acquired obesity biotech Metsera for $10bn aft a highly publicised bidding warfare with Novo Nordisk. Through the deal, Pfizer gained entree to long-lasting value nonaccomplishment candidates.

However, the drugmaker is taking a interruption from M&A this twelvemonth arsenic it looks to prioritise superior into advancing its ain pipeline. As per its Q2 net release, Pfizer said that it had injected $5.3bn into interior probe & improvement (R&D) truthful acold successful 2026.

Despite absent M&A, Pfizer did ink a licence statement with China-based Innovent Biologics successful May 2026. The deal, worthy much than $10bn, volition spot the 2 companies enactment unneurotic connected processing a twelve crab medications.

"Pfizer repels Covid-19 income tumble to rise 2026 guidance" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.